USPSTF: Evidence Lacking for Screening for Eating Disorders
Evidence insufficient to evaluate the benefits and harms of screening for eating disorders in adolescents and adults
Binge Eating Disorder
Dasotraline Development for ADHD, Binge Eating Disorder Halted, NDAs Withdrawn
n August 2018, the Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) stating the application required additional data to further assess the efficacy and tolerability of dasotraline.
Novel Binge Eating Disorder Treatment Accepted for Review by FDA
The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for dasotraline (Sunovion) in the treatment of binge eating disorder.
Dasotraline Effective in Phase 3 Binge Eating Disorder Trial
The results from this trial follow similar positive findings from a flexible-dose study of dasotraline.
